Cvijic to Sell 14,400 Neurogene Shares (NGNE) via J.P. Morgan

Rhea-AI Filing Summary

David & Christine Cvijic filed a Form 144 to sell 14,400 shares of common stock of Neurogene. The sale is to be effected through J.P. Morgan Securities LLC in an open‑market transaction. The filing notes a prior sale of 4,800 shares on 02/27/2026 for $120,526.27.

Insights

Securities Compliance Specialist

Form 144 filing notifies broker of intended Rule 144 sale; it's routine compliance paperwork.

The filing lists an open‑market sale of 14,400 shares to be handled by J.P. Morgan Securities LLC, which is a standard process under Rule 144 for restricted/controlled securities. The disclosed prior sale of 4,800 shares on 02/27/2026 for $120,526.27 is recorded in the same submission.

Timing and exact execution mechanics are not detailed here; subsequent transaction reports or broker confirmations will show completion. Cash flow treatment to the issuer is not stated in the excerpt.

Key Figures

Shares proposed for sale: 14,400 shares Prior sale in past 3 months: 4,800 shares Proceeds reported for prior sale: $120,526.27 +1 more

4 metrics

Shares proposed for sale 14,400 shares Form 144 listed open‑market sale

Prior sale in past 3 months 4,800 shares Sold on 02/27/2026

Proceeds reported for prior sale $120,526.27 Sale on 02/27/2026

Filing date shown 05/06/2026 Form 144 cover data

Key Terms

Form 144, Rule 144 sale / Open Market, Securities Sold During The Past 3 Months

3 terms

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rule 144 sale / Open Market regulatory

"Securities To Be Sold | Open Market"

Securities Sold During The Past 3 Months regulatory

"Common | 02/27/2026 | 4800 | 120526.27"

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	J.P. Morgan Securities LLC 270 Park Avenue - 10th Floor New York NY 10017	14400	416736	15574293	05/06/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/22/2024	Purchase	Open Market			14400	11/22/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David & Christine Cvijic Care of Neurogene Inc 535 W 24th St. - 5th Floor New York NY 10011	Common	02/27/2026	4800	120526.27

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Neurogene (NGNE) Form 144 filed by Cvijic mean?

It notifies a broker of an intended sale under Rule 144 by the reporting holders. The filing shows an intended open‑market sale of 14,400 shares through J.P. Morgan, with a prior sale of 4,800 shares on 02/27/2026.

How many shares are listed for sale in the Form 144 for NGNE?

The filing lists 14,400 shares of common stock proposed for sale. It also discloses a prior sale of 4,800 shares on 02/27/2026 for $120,526.27.

Who is handling the sale noted in the NGNE Form 144?

The sale is to be executed through J.P. Morgan Securities LLC. The filing cites an open‑market method and identifies the broker's New York address on the Form 144 cover details.

Does this Form 144 indicate proceeds go to Neurogene (NGNE)?

No cash‑flow recipient is specified in the excerpt. The Form 144 records selling holders and broker details but does not state whether proceeds, if any, are paid to the company.